Table 3.
Univariate analysis for overall survival.
| Variables | 3-year OS(%) | 95% for CI | χ2 | P |
|---|---|---|---|---|
| Age (year) | ||||
| <60 | 36.8 | 20.786-36.240 | 0.081 | 0.776 |
| ≥60 | 26.3 | 24.692-38.178 | ||
| Gender | ||||
| Male | 22.0 | 19.078-31.941 | 5.712 | 0.017 |
| Female | 37.1 | 29.449-49.265 | ||
| Tumor stage | ||||
| T1-T2 | 56.3 | 39.720-62.207 | 29.136 | <0.001 |
| T3-T4 | 13.6 | 15.708-24.337 | ||
| Lymph node metastasis | ||||
| No | 36.8 | 30.258-44.609 | 34.197 | <0.001 |
| Yes | 12.0 | 12.201-22.199 | ||
| Bismuth-Coretre type | ||||
| I-II | 48.5 | 34.778-56.871 | 33.125 | <0.001 |
| III-IV | 14.0 | 17.356-27.388 | ||
| Tumor differentiation | ||||
| Moderate/poor | 27.4 | 26.219-61.963 | 2.547 | 0.110 |
| well | 36.4 | 23.361-34.048 | ||
| Tumor size (cm) | ||||
| <3 | 32.1 | 26.310-43.763 | 0.501 | 0.479 |
| ≥3 | 22.2 | 21.407-35.497 | ||
| Liver invation | ||||
| No | 31.7 | 26.793-40.869 | 1.223 | 0.269 |
| Yes | 15.4 | 17.938-31.447 | ||
| Neural invasion | ||||
| No | 53.8 | 30.977-54.750 | 7.075 | 0.008 |
| Yes | 18.5 | 20.652-32.040 | ||
| Portal vein invasion | ||||
| No | 48.6 | 36.354-57.150 | 29.132 | <0.001 |
| Yes | 10.3 | 15.349-24.754 | ||
| Total bilirubin (μmol/L) | ||||
| <34.2 | 46.2 | 28.857-56.528 | 4.334 | 0.037 |
| ≥34.2 | 25.4 | 22.806-34.057 | ||
| CEA(ng/ml) | ||||
| <5.0 | 29.2 | 25.165-37.390 | 0.113 | 0.737 |
| ≥5.0 | 27.3 | 17.059-35.487 | ||
| CA19-9(U/ml) | ||||
| <37 | 52.0 | 33.711-57.617 | 10.674 | <0.001 |
| ≥37 | 17.6 | 19.344-30.094 | ||
| NLR | ||||
| <2.00 | 51.9 | 39.065-55.414 | 21.352 | 0.010 |
| ≥2.00 | 0.0 | 11.451-15.578 | ||
| PLR | ||||
| <117.60 | 44.0 | 27.703-49.363 | 2.660 | 0.103 |
| ≥117.60 | 21.2 | 21.734-34.252 | ||
| LMR | ||||
| <4.02 | 9.65 | 10.025-20.451 | 30.857 | <0.001 |
| ≥4.02 | 36.0 | 30.261-44.054 | ||
| CD3 | ||||
| <93.5 | 0.0 | 11.934-15.172 | 78.301 | <0.001 |
| ≥93.5 | 57.4 | 41.477-58.111 | ||
| CD4 | ||||
| <56.5 | 31.1 | 24.054-40.111 | 0.087 | 0.767 |
| ≥56.5 | 26.3 | 22.931-40.332 | ||
| CD8 | ||||
| <54.5 | 5.4 | 25.824-37.727 | 25.464 | 0.015 |
| ≥54.5 | 52.4 |
CEA, carcinoembryonic antigen; CA, 19-9 cancer antigen 19-9; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; LMR, lymphocyte monocyte ratio; OS, overall survival; CI, confidence interval.